Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome

Conclusion SS is a rare and aggressive type of CTCL that is refractory to current therapies. We report that CRs can be achieved in 3 methods: combined immunomodulatory therapy, targeted biologic agents, or total skin electron beams followed by nonablative allogeneic SCT. Micro-Abstract Sézary syndrome is a rare leukemic variant of primary cutaneous non-Hodgkin lymphomas that is difficult to treat. We report on 18 patients who had achieved long-term complete remission or response (CR) of ≥ 1 year and 7 patients who had achieved durable responses (DR) with subsequent relapse. The choices of therapy, including combined immunomodulatory therapy, biologic agents, and allogeneic stem cell transplants, have been shown to achieve CR in our patients.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research